RecruitingPhase 2NCT06599697

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

Studying Immune-mediated necrotizing myopathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Alabama at Birmingham
Principal Investigator: James Andrews, MD
University of Alabama at Birmingham
Intervention: Intravenously administered pooled human immunoglobulin (IVIG)(biological)
Enrollment: 12 target
Eligibility: 16 years · All sexes
Timeline: 2025 – 2027

Study locations (5)

University of Alabama at Birmingham, Birmingham, Alabama, United States
Johns Hopkins University, Baltimore, Maryland, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
University of Texas Health Science Center at Houston, Houston, Texas, United States
University of Washington, Seattle, Washington, United States

Collaborators

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Octapharma USA, Inc. · CSI Pharmacy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06599697 on ClinicalTrials.gov

Other trials for Immune-mediated necrotizing myopathy

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07103746
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
National Institute of Allergy and Infectious Diseases (NIAID)

See all trials for Immune-mediated necrotizing myopathy →

← Back to all trials